Gleevec price in India New product Didi Di 18310633404

In my country, chronic myeloid leukemia is the most common type of chronic leukemia. The incidence rate is relatively consistent at about ~ person/10,000 people. The main manifestations are fatigue, weight loss, low-grade fever, hepatosplenomegaly and malignant proliferation of bone marrow granulocytes. The incidence rate is ~ years old. The highest incidence rate among Chronic myeloid disease has a slow onset, and approximately 10% of chronic myeloid patients move from the stable phase to the blast phase in 20 years. Once blast crisis occurs, more than half of the cases die within 3 months, and only a few cases survive for more than 10 years. Therefore, blast crisis is the end-stage manifestation of chronic myeloidosis.

- Bristol-Myers Squibb Pharmaceutical Company of the United States and Novartis Pharmaceuticals of Switzerland have recently developed two new drugs for the treatment of chronic myeloid leukemia, which are expected to make up for the drug resistance shortcomings of Gleevec (), the current specific drug for the treatment of the disease. Although They are still in the second phase of clinical drug research, and generally new drugs can only enter the field of large-scale application after completing the third phase of clinical trials. However, these two new drugs have attracted the attention of the industry and patients because of their remarkable efficacy.